DLBCL >  DLBCL Lymphoma abstracts - ASH 2012

Last update: 11/13/2012

Grouped by:

Outcomes:
Reports | Auto SCT | Allo SCT | Novel Agents and Combination / RIT |
Preclinical | Patient Factors | Subtypes

Prognostic | PET imaging | Risk Factors

OUTCOME REPORTS

1. Durable Local Disease Control and Survival in Patients with Limited-Stage Diffuse Large B-Cell Lymphoma Receiving Involved-Node Radiation Therapy Plus Short-Course R-CHOP or CHOP Chemotherapy: Involved-Node Versus Involved-Field Radiation Therapy

2. Short Cycle of Immunochemotherapy Followed by Radiation Therapy Compared with Prolonged Cycles of Immunochemotherapy for Localized DLBCL : The Osaka Lymphoma Study Group (OLSG) Retrospective Analysis

3. Retrospective Study of Standard R-CHOP Therapy in Localized DLBCL

  Return

Outcomes: AUTO SCT

1. Autologous Stem Cell Transplantation with Yttriumm-90-Ibritumomab Tiuxetan (Zevalin) Plus BEAM Conditioning in Patients with Refractory Non-Hodgkin Diffuse Large B-Cell Lymphoma: Results of a Prospective, Multicenter, Phase II Clinical Trial

2. Efficacy of Autologous Stem-Cell Transplantation in Patients with Relapsed or Refractory Aggressive B-Cell Lymphoma in the Rituximab Era. A Multicenter Geltamo Study

3. 90-Yttrium Ibritumomab Tiuxetan (Zevalin) and BEAM Chemotherapy (Z-BEAM) Vs BEAM for Autologous Stem Cell Transplantation in Lymphoma: Toxicity and Long Term Outcome From a Retrospective Multicentric Study of 123 Patients

4. Safety and Efficacy of High-Dose Cyclophosphamide, Etoposide, and Ranimustine (CEM) Regimen Followed by Autologous Peripheral Blood Stem Cell Transplantation for Patients with High Risk De Novo Diffuse Large B-Cell Lymphoma or Diffuse Large B-Cell Lymphoma Associated with Follicular Lymphoma

5. Ricer (Rituximab, Ifosfamide, Carboplatin, Etoposide, Revlimid) Is Well-Tolerated Salvage Regimen in First Relapse/Primary Refractory DLBCL Allowing Consolidation with Autologous Stem Cell Transplant

6. Chemoimmunotherapy with R-CHOP or High Dose Sequential Therapy with Autologous Stem Cell Transplantation (R-HDS) for High Risk Diffuse Large B-Cell Lymphomas Patients: Results of the Randomized R-HDS0305 Trial by Gruppo Italiano Terapie Innovative Nei Linfomi (GITIL)

7. The Impact of Rituximab and Radiotherapy On Treatment Outcome of Patients with DLBCL and Skeletal Involvement

8. Risk Adapted-High Dose Therapies Modulate the Impact of Biological Classification in Diffuse Large B Cell Lymphoma Prognosis. Analysis of Biological Markers in Patients From Clinical Trials in Geltamo and Gotel Spanish Collaborative Groups

9. Autologous Stem Cell Transplantation with Yttriumm-90-Ibritumomab Tiuxetan (Zevalin) Plus BEAM Conditioning in Patients with Refractory Non-Hodgkin Diffuse Large B-Cell Lymphoma: Results of a Prospective, Multicenter, Phase II Clinical Trial

10. Outcomes of Patients with Refractory/Relapsed Diffuse Large B-Cell Lymphoma Who Progress After Autologous Stem Cell Transplantation in the Rituximab Era

11. Outcomes of Eam Conditioned Autologous Haematopoietic Stem Cell Transplantation for Lymphoma. A Matched Pairs Retrospective Single Centre Study Analysis

12. Upfront Consolidation Combining Yttrium-90 Ibritumomab Tiuxetan and High Dose Therapy with Stem-Cell Transplantation in Poor Risk Patients with Diffuse Large B-Cell Lymphoma

13. Combination of Lenalidomide with R-CHOP (R2CHOP) Is Well-Tolerated and Effective As Initial Therapy for Aggressive B-Cell Lymphomas - A Phase II Study

14. A Phase II Randomized Study of Lenalidomide or Lenalidomide and Rituximab As Maintenance Therapy Following R-CHOP Chemotherapy for Patients with High Risk Diffuse Large B-Cell Lymphoma

15. Non Pegilated Liposomal Doxorubicin (TLC-D99; Myocet ™) Can Be Safely and Effectively Used As Part of the R-COMP Regimen in Patients with Diffuse Large B-Cell Lymphoma Who Show Contraindications to Anthracyclines Due to Concomitant Moderate/Severe Heart Disease. Results of the HEART01 Phase II trial by the Fondazione Italiana Linfomi (NCT01009970)

16. Rituximab Dose-Dense Chemotherapy Followed by Intensified High-Dose Chemotherapy and Autologous Stem Cell Transplantation (HDC+ASCT) Significantly Reduces the Risk of Progression Compared to Standard Rituximab Dose-Dense Chemotherapy As First Line Treatment in Young Patients with High-Risk (aa-IPI 2-3) Diffuse Large B-Cell Lymphoma (DLBCL): Final Results of Phase III Randomized Trial DLCL04 of the Fondazione Italiana Linfomi (FIL)

17. Gemcitabine, Dexamethasone, Cisplatin (GDP) Compared to Dexamethasone, Cytarabine, Cisplatin (DHAP) Chemotherapy Prior to Autologous Stem Cell Transplantation for Relapsed and Refractory Aggressive Lymphomas: Final Results of the Randomized Phase III NCIC CTG Study LY12

18. Post Autologous Transplant Vorinostat (SAHA) in High Risk Lymphoma: Phase 1 Study of Vorinostat Maintenance

  Return

Outcomes: ALLO SCT

1. Alkylator-Based Conditioning for Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT) in Lymphoma: A Registry Study Comparing Thiotepa-, Busulfan-, Melphalan- and Treosulfan-Containing Regimens On Behalf of the EBMT Lymphoma Working Party

2. Allogenic Transplantation in Lymphomas: A Focused Analysis On Aggressive Lymphomas and Factors Predictive of Outcome in a Series of 179 Pts Treated At John Theurer Cancer Center

3. Clinical Effect of High-Dose, Donor-Derived Natural Killer Cells Infused After HLA-Haploidentical Hematopoietic Cell Transplantation

4. Donor Lymphocyte Infusion for Relapsed Hematological Malignancies After Allogeneic Hematopoietic Cell Transplantation: Prognostic Relevance of the Initial CD3+ T Cell Dose

5. BEAM-Campath Allogeneic Stem Cell Transplantation for Aggressive Non-Hodgkin’s Lymphomas. An Analysis of Outcomes From the BSBMT

6. Bortezomib and BEAM-Rituximab Reduced-Intensity Conditioning for High-Risk Lymphoma Patients Who Are Not Eligible for Nonmyeloablative Allogeneic Stem Cell Transplantation

7. Favorable Outcome in Patients with Lymphoid Malignancies Following Allogeneic Stem Cell Transplantation Using Fludarabine and Treosulfan As the Preparative Regimen

8. 731. Clinical Allogeneic and Autologous Transplantation - Results: Strategies to Prevent or Treat Relapse After Transplantation

9. Impact of Conditioning Regimen Intensity On the Outcomes of Allogeneic Hematopoietic Cell Transplantation for Refractory Grade-III Follicular (FL-III) and Diffuse Large B-Cell Lymphomas (DLBCL): A Cibmtr Analysis

10. Pre-Emptive T-Rapa Cell DLI for Therapy of High-Risk Lymphoma After Low-Intensity Allogeneic HCT

 Return

Outcomes: NOVEL AGENTS or COMBINATIONS

1. R-HCVAD Alternating with R-Methotrexate Cytarabine in Younger Patients (pts) with IH and High-Risk Age Adjusted-IPI DLBCL

2. R-CHOP21 Vs R-CHOP14 in 950 Diffuse Large B-Cell Lymphoma Patients: Results of a Multicentre Retrospective Study Form Italian Lymphoma Foundation (FIL)

3. Phase I/II Trial of Ofatumumab/Lenalidamide for Patients with Relasped/Refractory B-Cell Non-Hodgkin Lymphoma: High Response Rate in Indolent Lymphoma

4. Lenalidomide Is Effective in Heavily Pretreated Non Hodgkin Lymphoma (NHL): Analysis of a Retrospective Data Collection

5. Pilot Study of Lenalidomide-Rituximab Combination in Relapsed/Refractory Diffuse Large B Cell Lymphoma

6. Clinical Safety and Activity in a Phase 1 Trial of IPI-145, a Potent Inhibitor of Phosphoinositide-3-Kinase-δ,γ, in Patients with Advanced Hematologic Malignancies

7. Azacitidine Priming Prior to R-CHOP Is Feasible and Results in Global Demethylation, Restoration of TGF-Beta Pathway, and Improved Chemotherapy Sensitivity in Patients with Newly Diagnosed DLBCL

8. The Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), Has Preferential Activity in the ABC Subtype of Relapsed/Refractory De Novo Diffuse Large B-Cell Lymphoma (DLBCL): Interim Results of a Multicenter, Open-Label, Phase 2 Study

9. Sirtuin Inhibition in Combination with Histone Deacetylase (HDAC) Inhibition Is Effective Therapy for Aggressive B-Cell Lymphomas in Both Pre-Clinical and Clinical Studies of Disease

10. A Phase II Study of Sepantronium Bromide (YM155) Plus Rituximab in Previously Treated Subjects with Aggressive CD20-Positive B Cell Non-Hodgkin’s Lymphoma Who Are Ineligible for or Have Previously Received an Autologous Stem Cell Transplant - Stage I Results

11. Abexinostat (S78454 / PCI-24781), an Oral Pan-Histone Deacetylas (HDAC) Inhibitor in Patients with Refractory or Relapsed Hodgkin's Lymphoma, Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia. Results of a Phase I Dose-Escalation Study in 35 Patients

12. A Phase I Trial of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), in Combination with Rituximab (R) and Bendamustine in Patients with Relapsed/Refractory Non-Hodgkin’s Lymphoma (NHL)

13. MEDI-551, a Humanized Monoclonal Anti-CD19, in Adults with Relapsed or Refractory Advanced B-Cell Malignancies: Results From a Phase 1/2 Study

14. Clinical Safety and Activity in a Phase 1 Trial of IPI-145, a Potent Inhibitor of Phosphoinositide-3-Kinase-δ,γ, in Patients with Advanced Hematologic Malignancies

15. Biomimetic Synthetic High Density Lipoprotein Nanostructures Target the SR-B1 Receptor and Differentially Manipulate Cellular Cholesterol Flux in Lymphoma Cells: A Novel Treatment Paradigms

16. The BCL-2-Specific BH3-Mimetic ABT-199 (GDC-0199) Is Active and Well-Tolerated in Patients with Relapsed Non-Hodgkin Lymphoma: Interim Results of a Phase I Study

17. MLN0128 (INK128), an Investigational Oral Dual TORC1/2 Inhibitor, in Patients (pts) with Relapsed or Refractory Multiple Myeloma (MM), Non-Hodgkin’s Lymphoma (NHL), or Waldenstrom Macroglobulinemia (WM): Preliminary Results From a Phase 1 Dose-Escalation Study

18. Phase II Study of VEGF Inhibitor, PTK787/ZK222584, in Patients with Refractory or Relapsed Diffuse Large B-Cell Lymphoma

19. Full Dose Bendamustine (Treanda ®) Can Be Safely Combined with Rituximab, Etoposide and Carboplatin (TREC): Results of a Phase I Trial in Patients with Relapsed or Refractory Lymphoma

20. A Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory CD30-Positive Non-Hodgkin Lymphomas: Interim Results

21. A Phase I Study of DCDT2980S, an Antibody-Drug Conjugate (ADC) Targeting CD22, in Relapsed or Refractory B-Cell Non-Hodgkin’s Lymphoma (NHL)

22. Dual Targeted Therapy with the AKT Inhibitor Perifosine and the Multikinase Inhibitor Sorafenib in Patients with Relapsed/Refractory Lymphomas: Final Results of a Phase II Trial

23. A Phase I Study of the Anti-CD79b Antibody-Drug Conjugate (ADC) DCDS4501A Targeting CD79b in Relapsed or Refractory B-Cell Non-Hodgkin’s Lymphoma (NHL)

24. Phase 1 Study of Radiosensitization Using Bortezomib in Patients with Relapsed Non-Hodgkin’s Lymphoma Receiving Radioimmunotherapy

25. Rituximab-CHOP21 Plus Lenalidomide (LR-CHOP21) Is Effective and Feasible in Elderly Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Results of Phase II REAL07 Study of the Fondazione Italiana Linfomi (FIL)

26. Phase II Study of VEGF Inhibitor, PTK787/ZK222584, in Patients with Refractory or Relapsed Diffuse Large B-Cell Lymphoma

27. A Phase II Trial of Alemtuzumab (Campath) with DA-EPOCH-R in Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Hodgkin Lymphoma
    
    Outcomes: RIT:

28. A Phase II Trial of R-CHOP Followed by Zevalin Radioimmunotherapy for Patients with Previously Untreated Stages I and II CD20+ Diffuse Large Cell Non-Hodgkin's Lymphoma: an Eastern Cooperative Oncology Group Study (E3402)

29. Phase I Trial of Combination Therapy with 90y Ibritumomab Tiuxetan and Gemcitabine in Patients with Non-Hodgkin’s Lymphoma, Final Report

30. Combination Therapy Targeting Two Different Antigens with Anti-CD22 Radioimmunotherapy and Anti-CD20 Immunotherapy in Non-Hodgkin Lymphoma (NHL): Phase I Results

31. Rituximab-PECC Induction Followed by 90y-Ibritumomab Tiuxetan Consolidation in Relapsed or Refractory DLBCL Patients Who Are Not Eligible for or After ASCT: Preliminary Results From a Phase II HOVON Study

32. Consolidation Anti-CD22 Fractionated Radioimmunotherapy with 90y-Epratuzumab Tetraxetan Following R-CHOP in Elderly DLBCL Patients: A Lysa Phase II Prospective Trial

33. The Addition of Bevacizumab to Standard Therapy with R-CHOP in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma Is Associated with an Increased Rate of Cardiac Adverse Events: Final Analysis of Safety and Efficacy Outcomes From the Placebo-Controlled Phase 3 MAIN Study

34. Phase I Study of Intravenous PI3K Inhibitor Bay 80-6946: Preliminary Activity in Patients with Relapsed Non-Hodgkin Lymphoma (NHL) Treated in an MTD Expansion Cohort

 Return

 PRECLINICAL

1. The PI3K Inhibitor GS-1101 (CAL-101) Synergistically Potentiates HDAC-Induced Proliferation Inhibition and Apoptosis Through the Activation of JNK in Lymphoma Cells

2. IRAK4 Kinase As A Novel Therapeutic Target in the ABC Subtype of Diffuse Large B Cell Lymphoma

3. Preclinical Characterization of PWT143, a Novel Selective and Potent Phosphatidylinositol 3‑kinase Delta (PI3K delta) Inhibitor with Ex-Vivo Activity in Hematologic Malignancies

4. The Brd-Inhibitor OTX015 Is Active in Pre-Clinical Models of Mature B-Cell Lymphoid Tumors

5. Mechanisms of Sensitivity and Resistance to Histone Deacetylase Inhibitors in Diffuse Large B-Cell Lymphoma

6. Evaluation of the Anti-Tumor Activity of MLN4924, A Novel NEDD8 Activating Enzyme Inhibitor, in Pre-Clinical Models of Rituximab Chemotherapy-Sensitive or -Resistant B-Cell Lymphoma

7. Impact of Tumor Infiltrating T Cells in Patients with Diffuse Large B-Cell Lymphoma

8. AMG 319, a Novel Inhibitor of Phosphoinositide-3 Kinase Delta (PI3Kd), Demonstrates Activity in Lymphoma Pre-Clinical Models

9. Alisertib Added to Rituximab and Vincristine Is Synthetic Lethal and Curative of Double Hit Diffuse Large B-Cell Lymphoma in Mice

10. Inhibition of Autophagy by Chloroquine Sensitises Lymphoma Cells to ABT-737-Induced Apoptosis

11. Drug Development Targeting Microenvironment for Malignant Lymphoma

 Return

AGE, PATIENT and CLINICAL FACTORS

1. The Under-Treatment of Elderly Medicare Diffuse Large B-Cell Lymphoma Patients

2. Feasibility and Outcome of High Dose Therapy Followed by Autologous Stem Cell Transplantation in Relapsed/Refractory Lymphoma in the Geriatric Population

3. RIT with 90Y Ibritumomab Tiuxetan in Patients with Non-Hodgkin Lymphoma Over 65 Years

4. 901. Health Services and Outcomes Research: Poster II

5. Racial Disparities in Cell of Origin Among DLBCL Patients

6. Genome-Wide Analysis Uncovers Recurrent Alterations in Primary Central Nervous System Lymphomas

7. The Relationship of Depression and Anxiety and Impact of Cancer in Long-Term Survivors of Haematological Malignancy

8. Higher Body Mass Index Is Associated with an Increased Risk of Diffuse Large B-Cell Lymphoma

9. Outcome of Adolescent & Young Adult (AYA) Patients with Diffuse Large B-Cell Lymphoma (DLBCL)

10. Treatment of Diffuse Large B-Cell Lymphoma (DLBCL) Patients (pts) Age 80 and Older: Analysis of the Veterans Health Administration (VHA) National Database

11. Clinical Phase II Study of a Non-Anthracycline-Based Immunochemotherapy Regimen(R-GemOx) As First-Line Treatment in Elderly Patients with Diffuse Large B-Cell Lymphoma

12. A New Simplified Prognostic Index with Age Cut-off of 70 Years for Patients with Diffuse Large B-Cell Lymphoma. A Population-Based Analysis From the Danish Lymphoma Registry, LYFO

13. A Significant Better Two Year Survival in the Very Elderly Patients with a Diffuse Large B-Cell Lymphoma (DLBCL) Who Did Complete Standard Therapy: A Population-Based Cohort Study On Treatment, Toxicity and Outcome

14. Prognostic Importance of Comorbidity in a Population-Based Analysis of Patients with Advanced-Stage Diffuse Large B-Cell Lymphoma (DLBCL) Treated with R-CHOP

15. Health-Related Quality of Life in Older Patients Following Diffuse Large B-Cell Lymphoma (DLBCL) Diagnosis

16. What Is the Appropriate Dose Attenuation System of RCHOP for Elderly DLBCL Patients? - A Single Institutional Analysis in 115 Cosecutive Patients From Japan –

17. Prognostic Features, Treatments, and Disease-Specific Mortality Among Patients with Diffuse Large B-Cell Lymphoma Over the Age of 75: A Single-Center Retrospective Analysis

18. Impact of BMI On Treatment-Related Toxicity in United States Veterans with Diffuse Large B-Cell Lymphoma (DLBCL) Receiving CHOP+/-R

19. The Outcome of Primary Mediastinal Large B-Cell Lymphoma (PMBCL) in the R-CHOP Treatment Era

20. Impact of Reduced Dose Intensity for Elderly Patients with Diffuse Large B-CELL Lymphoma Receiving R-CHOP Every 14 or 21 Days: An Analysis of the LNH03-6B GELA Study

21. Efficacy and Safety of Reduced Dose Intensity R-CHOP in Elderly Patients with Diffuse Large B Cell Lymphom

  Return

SUBTYPES

1. Double Hit Lymphomas: Evaluation of Prognostic Factors and Impact of Therapy

2. Complete Response (CR) to Induction Therapy in Patients (pts) with Myc+ and Double Hit Non-Hodgkin’s Lymphoma (NHL) Is Associated with Prolonged Progression-Free Survival (PFS)

3. Survival and Clinicopathological Characteristics of EBV-Positive Diffuse Large B-Cell Lymphoma

4. Primary Breast Diffuse Large B Cell Lymphoma: A Distinct Clinical Entity

5. A Multicentric Prospective Phase 2 Study of Intravenous Rituximab and Intrathecal Liposomal Cytarabine in Combination with C5R Protocol Followed by Brain Radiotherapy for Immunocompetent Patients with Primary CNS Lymphoma: A Lymphoma Study Association (LYSA) Trial

6. Treatment of Secondary Central Nervous System Lymphoma with Intrathecal Rituximab, High Dose Methotrexate and R-DHAP, Followed by Autologous Stem Cell Transplantation. A Phase II HOVON Study

7. Prospective Cohort Study with Risk-Adapted Central Nervous System (CNS) Evaluation in Diffuse Large B-Cell Lymphoma Patients Treated with Rituximab-CHOP: Analysis of Incidence and Risk Factors for Secondary CNS Involvement

8. The Outcome of Primary Mediastinal Large B-Cell Lymphoma (PMBCL) in the R-CHOP Treatment Era

9. Primary Mediastinal B Cell Lymphoma Treated with CHOP-Like Chemotherapy with or without Rituximab: 5-Year Results of the Mabthera International Trial Group (MInT) Study

10. EBV(+) Diffuse Large B Cell Lymphoma Is Infrequent in Upper Central United States and Lacks Unique Clinical Characteristics or Adverse Prognosis Compared to EBV (-) Counterparts: Results From University of Iowa/Mayo Clinic SPORE

11. Diffuse Large B-Cell Transformation in Nodular Lymphocyte Predominant Hodgkin Lymphoma: Incidence, Risk Factors and Outcomes After a Forty-Year Experience From a Single Institution

12. Molecular Subtype Characterization of Formalin-Fixed, Paraffin-Embedded Diffuse Large B-Cell Lymphoma Samples on the Iceplex® System

13. The Presence of Intratumoral CD14 Positive Cells Is Associated with Transformation of Follicular Lymphoma to Diffuse Large B Cell Lymphoma

14. Histologic Transformation in Marginal Zone Lymphomas

 Return

 PROGNOSTIC

1. Predictive and Diagnostic Capabilities of Noninvasive MR Technology in Non-Hodgkin Lymphoma Patients

2. Prognostic Value of High Thymidine Kinase Activity in Previously Untreated Diffuse Large B-Cell Lymphoma Treated by R-CHOP

3. Newly Diagnosed Diffuse Large B-Cell Lymphoma Patients Treated with Immunochemotherapy Who Are Alive and Progression Free 12 Months After Diagnosis Have a Subsequent Overall Survival Similar to That of the General Population

4. Prognostic Factors for Patients with Diffuse Large B Cell Lymphoma and Transformed Indolent Lymphoma Undergoing Autologous Stem Cell Transplantation in the PET Era

5. Prognostic Factors for Patients with Diffuse Large B Cell Lymphoma and Transformed Indolent Lymphoma Undergoing Autologous Stem Cell Transplantation in the PET Era

6. Adverse Prognostic Impact of Vascular Endothelial Growth Factor Gene Polymorphism in Patients with Non-Hodgkin Lymphoma

7. Analysis of Prognostic Factors in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma and Skeletal Involvement: A Novel Simple Prognostic Score Identifies a Large Group of Low Risk Patients with an Excellent Prognosis

8. Absolute Monocyte Count At Diagnosis Is a Poor Prognostic Factor and Impacts Survival in Diffuse Large B-Cell Lymphoma: A Collaborative Multi-Center Study Involving 1026 Patients

9. Lenalidomide Efficacy in Activated B-Cell-Like Subtype Diffuse Large B-Cell Lymphoma Is Dependent Upon IRF4 and Cereblon Expression

10. Prognostic Impact of Serum Soluble Interleukin-2 Receptor Values Just After Completion of R-CHOP in Diffuse Large B-Cell Lymphoma

11. Decreased Brain FDG Uptake in Patients with Diffuse Large B Cell Lymphoma (cold brain) Is Associated with High Risk Disease and Predicts Poor Response to R-CHOP Chemotherapy

12. Double Hit Lymphomas: Evaluation of Prognostic Factors and Impact of TherapyPrognostic Impact of Serum Soluble Interleukin-2 Receptor Values Just After Completion of R-CHOP in Diffuse Large B-Cell Lymphoma

13. Expression but Not Promoter Hypermethylation of the Tyrosine Phosphatase PTPN6 Is Associated with Activated STAT3 and Inferior Prognosis in Diffuse Large B Cell Lymphoma Molecular Subtypes

14. Serum CCL3 and CCL4 Levels Function As Novel Prognostic Markers in Diffuse Large B Cell Lymphoma

15. Genome-Wide Analysis Uncovers Recurrent Alterations in Primary Central Nervous System Lymphomas

16. Mechanisms of Sensitivity and Resistance to Histone Deacetylase Inhibitors in Diffuse Large B-Cell Lymphoma

17. The Impact of Activated Akt Expression On Clinical Outcome in Diffuse Large B-Cell Lymphoma: A Clinicopathological Study of 99 Cases

18. MicroRNA Profiling in Low-Grade Ocular MALT and Diffuse Large B-Cell Lymphoma: A Role for MYC and NFKB1 Mediated Dysregulation of MicroRNA Expression in Aggressive Disease

19. Relationship Between HLA Class I and II Polymorphisms with Susceptibility and Clinical Outcome in Diffuse Large B-Cell Lymphoma

20. The Peripheral Blood Lymphocyte to Monocyte Ratio At Diagnosis Is a Potent Outcome Predictor in Diffuse Large B-Cell Lymphoma Treated with R-CHOP: A Long-Term Analysis On 973 Patients Receiving Chemotherapy with or without Rituximab

21. TP53 Mutation Is an Independent Predictor of Poor Survival in Untreated Patients with CD20+ Aggressive B-Cell Lymphoma: Analysis within the Ricover-60 Trial

22. A New Prognostic Score for Aggressive B-Cell Lymphoma with C-MYC Translocation Integrating Clinical and Genetic Features

23. A New Simplified Prognostic Index with Age Cut-off of 70 Years for Patients with Diffuse Large B-Cell Lymphoma. A Population-Based Analysis From the Danish Lymphoma Registry, LYFO

24. A Structural Basis for p53-Deficiency, Deregulated Cell Cycle and Unfavorable Outcome in Diffuse Large B-Cell Lymphoma

25. MYC Gene Simple Hit Is a Strong Independent Predictive Factor of Survival in Diffuse Large B-Cell Lymphomas in Contrast to MYC Double-Hit Gene Alterations: A Study by the Groupe d’Etude Des Lymphomes De l’Adulte

26. MYC Protein Expression, but Not High Grade Morphology, Is Associated with Poor Outcome in Non-Burkitt Diffuse Aggressive B-Cell Lymphomas: A SWOG S9704 Correlative Study

27. Expression of MYC, IgM, As Well As Non-Germinal Centre B-Cell Like Immunophenotype and Positive Immunofish Index Predict a Worse Progression Free Survival and Overall Survival in a Series of 670 De Novo Diffuse Large B-Cell Lymphomas Included in Clinical Trials : A GELA Study of the 2003 Program

28. Can Global Protein Expression Profiling Determine Prognosis in Diffuse Large B-Cell Lymphoma?

29. Reversing Metabolic and Epigenetic Cellular Alterations to Overcome Chemo-Resistance in Aggressive B Cell Lymphomas

30. Diffuse Large B-Cell Lymphomas Utilize Endogenous and Exogenous Fatty Acids for Cell Growth and Survival

31. Impact of Obesity and Genetic Variation in Energy Balance and Metabolism Genes On Prognosis in Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL)

32. Alternative Splicing and Expression of Class II Tubulin Beta (TUBB2B) Are Associated with Outcome in Diffuse Large B-Cell Lymphoma

33. Tumor Associated Macrophage Expression, CD163, Is Associated with Poorer Outcome in Diffuse Large B-Cell Lymphoma

34. CD30 Expression in Diffuse Large B-Cell Lymphoma and Its Relation to Important Clinical and Biological Disease Features

35. Alternative Splicing and Expression of Class II Tubulin Beta (TUBB2B) Are Associated with Outcome in Diffuse Large B-Cell Lymphoma

36. Fatty Acid Metabolism in Diffuse Large B-Cell Lymphoma (DLBCL): Interaction with Oncogenic Cell Signaling Pathways and the Identification of a Novel Treatment Paradigm

37. Biological Significance of the Immumoproteasome Subunits Mecl-1 and LMP-2 in Diffuse Large B-Cell Lymphoma

38. Diffuse-Large-B-Cell Lymphoma Patients with Secretory IgM Monoclonal Component Are A Very Poor Prognostic Subset

39. Enhancer Profiling Reveals SOX9 As a Novel Transcription Regulator of B Cell Activation and DLBCL Transformation

40. Combinatorial Targeting of BCL6 and Anti-Apoptotic Proteins in Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL)

41. Serum Metabolomics Uncovers a New Therapeutic Target in Diffuse Large B Cell Lymphoma (DLBCL)

42. Expression of MYC but Not pSTAT3 Is an Adverse Prognostic Factor for Diffuse Large B Cell Lymphoma (DLBCL) Treated with Epratuzumab/R-CHOP

43. The Diffuse Large B-Cell Lymphoma Infiltrating Macrophage Transcriptome Signature Is Enriched for Both M1 and M2 Genes and Provides an Excellent Platform for Functional Validation of Macrophage Biology in DLBCL

44. The Direct Anti-Tumor Activity of Enzastaurin (LY317615.HCl) and Its Primary Metabolite (LY326020.HCl) Is Evident in Preclinical DLBCL Models Regardless of Molecular Subtype

45. Rituximab Sensitivity to De Novo DLBCL Cells Showing the Specific Phenotype of CD20 Protein Immunohistochemistry-Positive / Flow Cytometory-Negative: Analyses of Its Clinical Significances and the Molecular Mechanisms

46. SOCS1 Mutation Subtypes Predict Divergent Outcomes in DLBCL Patients

47. Prognositc Inpact of Tumor-Infiltrating FOXP3 + Regulatory T Cells in DLBCL Treated with R-CHOP

48. Integrated Analysis of High-Resolution Gene Expression and Copy Number Profiling Identified Biallelic Deletion of CDKN2A/2B Tumor Suppressor Locus As the Most Frequent and Unique Genomic Abnormality in Diffuse Large B-Cell Lymphoma (DLBCL) with Strong Prognostic Value in Both GCB and ABC Subtypes and Not Overcome by a Dose-Intensive Immunochemotherapy Regimen Plus Rituximab. Results of a Prospective GELA Clinical Trial Program

49. An Enhanced International Prognostic Index (IPI) for Patients with Diffuse Large B-Cell Lymphoma (DLBCL) in the Rituximab Era Using the National Comprehensive Cancer Network (NCCN) Database

50. Large-Scale High Resolution Integration of Copy Number and Gene Expression in DLBCL Reveals Focal and Frequent Deletions in Chromatin Modifying Genes with Outcome Correlation

51. Prognostic Significance and Phenotypic Manifestations of MYC/BCL2 Protein Expression in Diffuse Large B-Cell Lymphoma (DLBCL) with Extranodal Organ Involvement: A Report of the International DLBCL Rituximab-CHOP Consortium Program Study

52. Distinct Phenotypic and Functional Immunological Alterations Characterize the Peripheral Blood Compartment of Patients with Diffuse Large B Cell Lymphoma (DLBCL)

53. MYC Translocation Partner Gene Determines Survival in Large B-Cell Lymphoma with MYC- or Double Hit MYC/BCL2 Translocation

54. MiR-181a Is a Master Regulator of the Nuclear Factor-κB Signaling Pathway in Diffuse Large B Cell Lymphoma

 Return

 BIOMARKER FOR DISEASE

1. Detection of Diffuse Large B-Cell Lymphoma in Peripheral Blood Using High-Throughput Sequencing Assay

 Return

PET IMAGING

1. FDG-PET/CT Metabolic Tumor Volume: A New Prognostic Marker in Hodgkin Lymphoma?

2. Combined Analysis Using Visual and SUV-Based Quantitative Assessments Improves Predictive Value of Interim Positron Emission Tomography Scan in Diffuse Large B-Cell Lymphoma Treated with R-CHOP

3. Prognostic Impact of Clinician-Based Interpretation of FDG-PET/CT Reports Obtained in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma

4. Evaluation of Dual Tracer (FLT and FDG) PET Imaging As Part of Risk-Adapted Therapy for Patients with Advanced Stage Diffuse Large B Cell Lymphoma (DLBCL)

5. Pre-Transplant FDG-PET Scan Lacks Prognostic Value in Chemosensitive B-Cell Non-Hodgkin Lymphoma Patients Undergoing Non-Myeloablative Allogeneic Stem Cell Transplantation

6. Surveillance PET-CT Scanning Is Useful in the First 18 Months Following Completion of Therapy for Patients with Diffuse Large B-Cell Lymphoma with IPI≥3

7. Role of Positron Emission Tomography (PET/CT) in Primary Mediastinal Large B Cell Lymphoma (PMLBCL): Preliminary Results of an International Phase II Trial (IELSG-26 Study) Conducted On Behalf of the International Extranodal Lymphoma Study Group (IELSG), the Fondazione Italiana Linfomi (FIL) and the UK NCRI Lymphoma Group

8. Is Interim/Mid-Treatment PET (interim PET, i-PET) Scan Predictive of Outcome in Diffuse Large B-Cell Lymphoma?

9. Response-Adapted Therapy for Diffuse Large B-Cell Non-Hodgkin's Lymphoma (DLBCL)Based On Early [18F] FDG-PET Scanning: An Eastern Cooperative Oncology Group Study (E3404)

10. Baseline Metabolic Tumor Volume Is Predictive of Patient Outcome in Diffuse Large B Cell Lymphoma

 Return

RISK FACTORS

1. Hepatitis B Virus (HBV) Screening in Hematology/Oncology Patients Who Receive Rituximab: Continued Need for Evidence-Based Standardized Recommendations and Effective Implementation Into Clinical Practice

2. Hepatitis B Infection Is Associated with an Increased Risk of Non-Hodgkin Lymphoma: A Meta-Analysis

 Return

 

See also Other Ways to Help